A Double-Blind, Placebo-Controlled Pilot Investigation of the Safety of Intranasal Glulisine in Down Syndrome
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Insulin glulisine (Primary)
- Indications Down syndrome
- Focus Adverse reactions; Therapeutic Use
- 10 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 10 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 06 May 2015 New trial record